2021, Number 2
Rev Hematol Mex 2021; 22 (2)
Experience at a hematology center of Mexico City in a group of patients with benign and malignant diseases infected by SARS-CoV-2 virus
Quintero-Hernández CE, Reynoso-Gómez EE
Full text
Language: Spanish
References: 11
Page: 63-68
PDF size: 163.27 Kb.
ABSTRACT
Background: COVID-19 outbreak has generated uncertainty about the outcome of patients with hematological disorders and concern about therapeutic interventions could aggravate the risk of contagiousness. Multiple retrospective analyses have shown a higher mortality rate for individuals with hematological malignancies.Objective: To communicate our experience in an hemato-oncological center of Mexico City in patients with COVID-19.
Materials and Methods: A descriptive analysis of patients with benign and malignant hematological diseases with the diagnosis of COVID-19 performed from March 2020 to February 2021 in an outpatient hemato-oncology center in Mexico City.
Results: Eighteen patients were infected, most of them women, with a median age of 49.5 years. Ten patients had a malignant condition and 10 received an active treatment. Three required admission to hospital. Of those requiring imaging studies, 13 had a documented pneumonia. Hematological findings with prognostic implication were: lymphopenia (n = 3), thrombocytopenia (n = 3) and anemia (n = 1). Only one patient died.
Conclusions: COVID-19 mortality rate in patients with hematologic malignancy is higher than in general population. Active treatment of these conditions does not necessarily increase mortality and as it might improve the outcome of the hematological disease, we believe it is not always justified to stop or delay it.
REFERENCES
Passamonti F, Cattaneo C, Arcaini L, Bruna R, et. al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 2020; 7: e737-45. doi. https://doi.org/10.1016/ S2352-3026(20)30251-9.